Alzheimer's Disease and the Routine Clinical Use of CSF Biomarkers

Author(s): Alessandro Martorana* .

Journal Name: CNS & Neurological Disorders - Drug Targets

Volume 16 , Issue 4 , 2017

Become EABM
Become Reviewer

Graphical Abstract:


Abstract:

Amyloid based hypothesis led to develop biomarkers oriented diagnosis of neurodegenerative dementias. Among them biomarkers for AD, the most diffuse form of dementia, are currently the unique available for scientific and diagnostic purposes. CSF biomarkers like Amyloid beta 42, total tau and phosphorylated tau levels can be easily evaluated in individuals suffering from cognitive decline, to diagnose or exclude AD type dementia, since early stages. Moreover, their analysis gave the opportunity to better understand cognitive decline patho-physiology during aging. Experience from their use and analysis however showed a high degree of variability due to the great heterogeneity of AD on one hand, the presence of isolated CSF biomarker changes that are not to be considered of AD type and deserve a clinico-pathological classification on the other. Aim of this review is to offer the knowledge about CSF biomarker’s use in clinics.

Keywords: AD, amyloidopathy, biomarkers, CSF, diagnosis, suspected non-Alzheimer's pathology, tauopathy.

Rights & PermissionsPrintExport Cite as

Article Details

VOLUME: 16
ISSUE: 4
Year: 2017
Page: [407 - 413]
Pages: 7
DOI: 10.2174/1871527316666170124164854
Price: $58

Article Metrics

PDF: 33
HTML: 2